Wednesday, 23 May 2018

TZD – what is TZD?

TZD stands for thiazolidinedione, or glitazone. TZD is a medication to treat insulin resistance. It lowers insulin resistance and glucose levels and makes the body more sensitive to the effects of insulin. As a result, glucose is able to enter the cells and perform normal physiological actions. TZD also reduces the amount of glucose produced by the liver.

What are the available TZD medications?

There are two TZDs – Rosiglitazone (Avandia) and Pioglitazone (Actos). The dosage of these medications is determined by a qualified medical practitioner.

TZD is a medication to treat insulin resistance. TZD stands for thiazolidinedione, or glitazone.


What are the beneficial effects of TZD?

Apart from controlling blood glucose levels, TZDs might also raise the “good” cholesterol or HDL (high density lipoprotein). HDL helps keep the blood vessels from getting blocked by removing harmful fat deposits that cause atherosclerosis. It could also lower blood pressure and reduce fatty liver.

What are the adverse side effects of TZD?

TZD can increase the risk of chronic heart disease. They can make existing chronic heart disease worse. It can lead to fluid build-up in the body leading to swollen ankles, legs and lungs. Sometimes it can lead to breathlessness. They can also increase the risk of broken bones and cause anemia. Pioglitazone can decrease the effectiveness of birth control pills.

What does TZD do to the body?

After consumption, TZD enters circulation and activates a molecule called peroxisome proliferator-activated receptor gamma. This molecule is abundant in skeletal muscles, fat tissues, and the liver. When peroxisome proliferator-activated receptor gamma is activated by TZD, it improves the action of insulin and makes the cells to become sensitive to insulin. As a result the cells take up glucose and the levels of glucose and insulin levels go down. This leads to the control of blood glucose levels in diabetic patients. Sometimes TZD is taken in conjunction with Metformin.

No comments:

Post a Comment